JAK2(V617F) myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML

Interferon α (IFNα) is used to treat JAK2(V617F)-driven myeloproliferative neoplasms (MPNs) but rarely clears the disease. We investigated the IFNα mechanism of action focusing on PML, an interferon target and key senescence gene whose targeting by arsenic trioxide (ATO) drives eradication of acute...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Exp Med
Autors principals: Dagher, Tracy, Maslah, Nabih, Edmond, Valérie, Cassinat, Bruno, Vainchenker, William, Giraudier, Stéphane, Pasquier, Florence, Verger, Emmanuelle, Niwa-Kawakita, Michiko, Lallemand-Breitenbach, Valérie, Plo, Isabelle, Kiladjian, Jean-Jacques, Villeval, Jean-Luc, de Thé, Hugues
Format: Artigo
Idioma:Inglês
Publicat: Rockefeller University Press 2020
Matèries:
Brief Definitive Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7579737/
https://ncbi.nlm.nih.gov/pubmed/33075130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20201268
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars